Bio‑Rad Cuts 2026 Outlook, Shares Drop 9.5%

Bio‑Rad shares fell 9.5% to $253.48 after cutting its 2026 revenue outlook to –3% to +0.5% from prior 0.5%‑1.5% growth range.
First‑quarter net loss of $527.1 million versus $64 million profit a year earlier, driven by a fair‑value loss on Sartorius AG investment.
Adjusted Q1 earnings per share were $1.89, missing the LSEG consensus of $1.98, and the stock is down 16.7% year‑to‑date.